Hereditary Neuropathy with Liability to Pressure Palsies Unmasked by Polatuzumab Vedotin-containing Chemotherapy

We report the case of a 49-year-old man with hereditary neuropathy with liability to pressure palsies unmasked by polatuzumab vedotin-containing chemotherapy. Neuropathic symptoms were predominant in areas surrounding the right and left ulnar nerves after the first course of chemotherapy. However, they progressed in a stepwise manner, involving other limb regions, after the second and third courses. Nerve conduction studies revealed demyelinating neuropathy conspicuous at the compression sites, and fluorescence in situ hybridization showed deletion of the PMP22 gene. This case underscores the importance of considering the development or exacerbation of hereditary neuropathies including hereditary neuropathy with liability to pressure palsies in patients receiving polatuzumab vedotin.